Literature DB >> 16293911

New classification and treatment for myotonic disorders.

Teruyuki Kurihara1.   

Abstract

Myotonia is repetitive firing of muscle action potentials causing prolonged muscle contractions even after mechanical stimulations to the muscles have ceased. Most common myotonic disorder is myotonic dystrophy which is now termed DM1, myotonic dystrophy type 1. In Japan, proximal myotonic myopathy, which is now called DM2 has not been reported. Both DM1 and DM2 have Cl channel abnormality which causes myotonia. Less commonly we encounter Thomsen's disease, and autosomal recessive generalized myotonia (Becker type) which also have a Cl channel abnormality. There are other myotonic disorders related to Na channelopathy which include three disorders: paramyotonia congenita, adynamia episodica hereditaria, and myotonia fluctuans. Myotonia has been treated by various Na channel blockers, mexiletine, phenytoin, and carbamazepine, but they were originally developed for cardiac arrhythmia, or seizure disorders and they have undesirable side effects, weakness. Comprehensive treatment includes myotonia control without reducing the strength, and care for systemic manifestations of DM1.

Entities:  

Mesh:

Year:  2005        PMID: 16293911     DOI: 10.2169/internalmedicine.44.1027

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

1.  Case 12: my doctor says that I have ALS!

Authors:  Robin K Wilson; Vinay Chaudhry
Journal:  MedGenMed       Date:  2006-03-22

2.  Two cases of myotonic dystrophy manifesting various ophthalmic findings with genetic evaluation.

Authors:  Min Ji Kang; Hye Bin Yim; Hyung Bin Hwang
Journal:  Indian J Ophthalmol       Date:  2016-07       Impact factor: 1.848

3.  Dystrophia myotonica type 1 presenting with dysarthria: A case report and literature review.

Authors:  Chunrong Li; Xiaoling Zhang; Chunkui Zhou; Lijun Zhu; Kangding Liu; Shaokuan Fang
Journal:  Exp Ther Med       Date:  2017-06-12       Impact factor: 2.447

4.  Mitochonic Acid 5 Improves Duchenne Muscular Dystrophy and Parkinson's Disease Model of Caenorhabditis elegans.

Authors:  Xintong Wu; Satoi Nagasawa; Kasumi Muto; Maiko Ueda; Chitose Suzuki; Takaaki Abe; Atsushi Higashitani
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

5.  Identification and characterization of DM1 patients by a new diagnostic certified assay: neuromuscular and cardiac assessments.

Authors:  Rea Valaperta; Valeria Sansone; Fortunata Lombardi; Chiara Verdelli; Alessio Colombo; Massimiliano Valisi; Elisa Brigonzi; Elena Costa; Giovanni Meola
Journal:  Biomed Res Int       Date:  2013-05-09       Impact factor: 3.411

6.  Genetic and chemical modifiers of a CUG toxicity model in Drosophila.

Authors:  Amparo Garcia-Lopez; Lidon Monferrer; Irma Garcia-Alcover; Marta Vicente-Crespo; M Carmen Alvarez-Abril; Ruben D Artero
Journal:  PLoS One       Date:  2008-02-13       Impact factor: 3.240

7.  Nonsustained ventricular tachycardia does not affect the prognosis of neuromuscular diseases: A preliminary and retrospective study.

Authors:  Takahiro Kamihara; Fumihiko Yasuma; Toyoaki Murohara
Journal:  J Arrhythm       Date:  2018-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.